We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M Turnover 18.46%
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+10.01%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$111M
AUM Growth
+$2.3M
Cap. Flow
+$4.8M
Cap. Flow %
4.31%
Top 10 Hldgs %
45.14%
Holding
70
New
3
Increased
23
Reduced
5
Closed
7
Avg Time Held Equity + Options
1.4 years
Top 10 Avg Time Held Equity + Options
0.7 years
Top 20 Avg Time Held Equity + Options
1 year
Avg Time Held Equity only
1.4 years
Top 10 Avg Time Held Equity only
0.8 years
Top 20 Avg Time Held Equity only
1.2 years

Top Buys

Rank Stock Value
1
BIVV
Bioverativ Inc. Common Stock
BIVV
+$648K
2
UTHR icon
United Therapeutics
UTHR
+$525K
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$509K
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$340K
5
SGEN
Seagen Inc. Common Stock
SGEN
+$316K

Top Sells

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$613K
2
MYGN icon
Myriad Genetics
MYGN
+$527K
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$404K
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$220K
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$140K

Sector Composition

Rank Sector Weight
1 Healthcare 73.61%
2 Miscellaneous 26.05%
3 Real Estate 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CKPT icon
51
DELISTED
Checkpoint Therapeutics
CKPT
$507K 0.45%
11,276
-500
-4% -$43.4K
2017 Q2
1 quarter
UTHR icon
52
United Therapeutics
UTHR
$23.6B
$481K 0.43%
+4,108
New +$525K
2017 Q3
0 quarters
PGEN icon
53
Precigen
PGEN
$2.64B
$455K 0.41%
23,928
+5,583
+30% +$115K
2016 Q4
3 quarters
AKBA icon
54
Akebia Therapeutics
AKBA
$196M
$413K 0.37%
21,009
– –
2017 Q1
2 quarters
SNR
55
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$383K 0.34%
41,850
– –
2016 Q1
6 quarters
ICPT
56
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$260K 0.23%
4,481
+2,661
+146% +$287K
2016 Q3
4 quarters
HRTX icon
57
Heron Therapeutics
HRTX
$71.2M
$256K 0.23%
15,874
– –
2017 Q1
2 quarters
AVXS
58
DELISTED
AveXis, Inc. Common Stock
AVXS
$242K 0.22%
2,500
– –
2016 Q4
3 quarters
SCTL
59
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$227K 0.2%
28,133
– –
2016 Q4
3 quarters
LGND icon
60
Ligand Pharmaceuticals
LGND
$6.01B
$207K 0.19%
2,435
-952
-28% -$75.4K
2016 Q4
3 quarters
CFRX
61
DELISTED
ContraFect Corporation
CFRX
$167K 0.15%
188
– –
2016 Q3
4 quarters
SCYX icon
62
SCYNEXIS
SCYX
$38.7M
$161K 0.14%
833
– –
2017 Q1
2 quarters
PGNX
63
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$160K 0.14%
21,782
– –
2017 Q1
2 quarters
BIB icon
64
PUT
ProShares Ultra NASDAQ Biotechnology
BIB
$93.9M
– –
-42,500
Closed -$2.27M –
IBB icon
65
PUT
iShares Biotechnology ETF
IBB
$10.7B
– –
-37,500
Closed -$3.88M –
IOVA icon
66
Iovance Biotherapeutics
IOVA
$6.51B
– –
-29,934
Closed -$220K –
MYGN icon
67
Myriad Genetics
MYGN
$420M
– –
-20,414
Closed -$527K –
XBI icon
68
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.91B
– –
-65,000
Closed -$5.02M –
SIOX
69
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-2,178
Closed -$404K –
KITE
70
DELISTED
Kite Pharma, Inc.
KITE
– –
-5,915
Closed -$613K –
1 2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q3 2017 Portfolio in Review

As of Q3 2017, Opus Point Partners Management held 70 positions worth $111M, up 2.1% from $109M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Opus Point Partners Management deployed $4.8M of net new capital in Q3 2017, opening 3 new positions and adding to 23 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 11,056 shares worth $631K.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 66% a quarter earlier, followed by Miscellaneous and Real Estate.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $140K trimmed.

  • Opus Point Partners Management's largest Q3 2017 buy was Bioverativ Inc. Common Stock: 11,056 shares worth $631K.
  • Opus Point Partners Management added most to Ultragenyx Pharmaceutical in Q3 2017, an estimated $340K increase.
  • Opus Point Partners Management's biggest Q3 2017 reduction was Alnylam Pharmaceuticals, cutting an estimated $140K.
  • Opus Point Partners Management fully exited Kite Pharma, Inc. in Q3 2017, selling an estimated $613K.
  • Opus Point Partners Management's ten largest holdings make up 45% of its $111M portfolio in Q3 2017.
  • Opus Point Partners Management opened 3 new positions and closed 7 in Q3 2017.
  • Opus Point Partners Management's portfolio value rose 2.1% quarter-over-quarter to $111M.

Based on Opus Point Partners Management's 13F filing for Q3 2017, filed 14 Nov 2017.